白斑症市场:KOL的洞察

本报告提供全球白斑症市场相关调查，市场概要，以及已通过核准治疗方法，开发平台趋势，未来预测等资讯。

目录

摘要整理

白斑症的治疗流程

调查目的

Janus激酶(JAK)抑制剂

• 已上市治疗方法
  • Opzelura (ruxolitinib; Incyte Corporation)
• 开发平台疗法
  • Ritlecitinib (PF 6651600; Pfizer)
  • Rinvoq (upadacitinib; AbbVie)
  • Povorcitinib (INCB054707; Incyte Corporation)

PDE4抑制剂

• 开发平台疗法
  • Crisaborole (AN-2728)及PF 07038124(Pfizer)

单株抗体

• 开发平台疗法
  • Ordesekimab(AMG 714，Amgen)
  • EB06(NI-0801，Edesa Biotech/Light Chain Biosciences)

MC1R促效剂

• 开发平台疗法
  • Scenesse(Afamelanotide，Clinuvel Pharmaceuticals)

白斑症的今后治疗趋势

• 重要洞察的彙整

附录

While KOLs say Incyte Corporation's Opzelura is a significant advance over existing treatments for vitiligo, what factors do they identify that could initially limit uptake? Why are dermatologists sceptical about the prospects for Pfizer's pipeline JAK inhibitor ritlecitinib in vitiligo? What advantages do KOLs see for IL-15 inhibitors such as Amgen's ordesekimab? KOLs critically assess the prospects of launched and pipeline therapies.

Table of Contents

Executive summary

Treatment algorithm for vitiligo

Research objectives

Janus kinase (JAK) inhibitors

• Marketed therapies
  • Opzelura (ruxolitinib; Incyte Corporation)
• Pipeline therapies
  • Ritlecitinib (PF 6651600; Pfizer)
  • Rinvoq (upadacitinib; AbbVie)
  • Povorcitinib (INCB054707; Incyte Corporation)

PDE4 Inhibitors

• Pipeline therapies
  • Crisaborole (AN-2728) and PF 07038124 (Pfizer)

Monoclonal antibodies

• Pipeline therapies
  • Ordesekimab (AMG 714; Amgen)
  • EB06 (NI-0801; Edesa Biotech/Light Chain Biosciences)

MC1R agonist

• Pipeline therapies
  • Scenesse (Afamelanotide; Clinuvel Pharmaceuticals)

Future treatment trends in vitiligo

• Key insights summary

Appendix

• KOL details
  • KOLs from the US
  • KOLs from Europe